Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 8/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936129 | 0.87 | BCHE (0.53) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL935633 | 0.84 | CHRNA7 (0.55) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL21059211 | 0.81 | MEN1 (0.52) | MAPTEPHX2 | |
| SCHEMBL28579742 | 0.79 | ADRB2 (0.51) | MAPTEPHX2 | |
| SCHEMBL28585302 | 0.79 | ADRB2 (0.51) | MAPTEPHX2 | |
| SCHEMBL28579744 | 0.79 | ADRB2 (0.51) | MAPTEPHX2 | |
| SCHEMBL25403778 | 0.77 | DPP4 (0.52) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL27101573 | 0.77 | DPP4 (0.52) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL25403020 | 0.77 | DPP4 (0.52) | BCHEMAOBDPP4DPP7PREP | |
| SCHEMBL22534436 | 0.76 | RHOA (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021569-A1 | Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER, UNIVERSITE (FR) | 2011-01-27 | — | — | US | disclosed |
| WO-2011010015-A1 | PIPERIDINE COMPOUNDS, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-01-27 | — | — | WO | disclosed |
| EP-2277863-A1 | Piperidine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021569-A1 | Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | BDNF, GRIN2C, GRIN2A | BCHE 66/4885MAOB 223/4885MAPT 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.